<p>Recursion Pharmaceuticals, Inc.（納斯達克代碼：RXRX - 獲取免費報告）週一的交易量強勁。交易中共成交 9,916,028 股，較前一交易日的 11,771,491 股下降了 16%。該股最後交易價格為 5.68 美元，前一交易日收盤價為 5.76 美元。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>突然崛起：Recursion Pharmaceuticals 是 NVIDIA 的 AI 寵兒嗎？</li>
</ul>
<p>RXRX 一直是多份分析師報告的主題。Leerink Partners 在 2 月 28 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 7.00 美元下調至 6.00 美元，並對該股給予 “市場表現” 評級。摩根士丹利在週四的研究報告中將 Recursion Pharmaceuticals 的目標價從 10.00 美元下調至 8.00 美元，並給予 “等權重” 評級。Cowen 在 2 月 28 日的研究報告中重申了對 Recursion Pharmaceuticals 的 “持有” 評級。KeyCorp 在 1 月 8 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 12.00 美元下調至 10.00 美元，並給予 “超配” 評級。最後，Needham &amp; Company LLC 在 4 月 8 日的研究報告中重申了 “買入” 評級，並對 Recursion Pharmaceuticals 的目標價設定為 11.00 美元。四位分析師對該股給予 “持有” 評級，兩位分析師給予 “買入” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “持有”，平均目標價為 8.20 美元。</p>
<p><strong>查看我們對 RXRX 的最新分析</strong></p>
<h2>Recursion Pharmaceuticals 價格表現</h2>
<ul>
<li>生物科技處於邊緣：兩隻潛力巨大的股票</li>
</ul>
<p>該股的 50 日移動平均價格為 6.83 美元，200 日移動平均價格也為 6.83 美元。該公司的市值為 21.9 億美元，市盈率為-3.56，貝塔值為 1.00。公司的債務與股本比率為 0.04，流動比率為 4.35，速動比率為 4.35。</p>
<p>Recursion Pharmaceuticals（納斯達克代碼：RXRX - 獲取免費報告）最近在 2 月 28 日發佈了季度財報。公司報告季度每股收益（EPS）為-0.53 美元，低於分析師共識預期的-0.36 美元，差距為-0.17 美元。該季度的營業收入為 460 萬美元，而分析師預期為 1904 萬美元。Recursion Pharmaceuticals 的淨利潤率為-579.52%，股本回報率為-76.56%。該公司的收入同比下降了 57.8%。在去年同期，該公司每股收益為-0.42 美元。整體來看，股票分析師預計 Recursion Pharmaceuticals, Inc.在當前財年將發佈-1.57 美元的每股收益。</p>
<h2>Recursion Pharmaceuticals 的機構交易</h2>
<ul>
<li>AI 製藥：通往 AI 驅動藥物投資的兩條路徑</li>
</ul>
<p>大型投資者最近增加或減少了對該股的持倉。Vanguard Group Inc.在第四季度將其在 Recursion Pharmaceuticals 的持倉增加了 40.1%。Vanguard Group Inc.目前擁有 34,009,994 股該公司的股票，價值 229,908,000 美元，此前在上個季度增持了 9,737,196 股。軟銀集團在第四季度購買了 Recursion Pharmaceuticals 的新股份，價值約為 99,152,000 美元。State Street Corp 在第三季度將其在 Recursion Pharmaceuticals 的持倉增加了 47.1%。State Street Corp 目前擁有 12,870,272 股該公司的股票，價值 84,815,000 美元，此前在上個季度增持了 4,120,685 股。Novo Holdings A S 在第四季度購買了 Recursion Pharmaceuticals 的新股份，價值約為 68,375,000 美元。最後，Geode Capital Management LLC 在第四季度將其在 Recursion Pharmaceuticals 的持倉增加了 12.1%。Geode Capital Management LLC 目前擁有 6,087,149 股該公司的股票，價值 41,160,000 美元，此前在上個季度增持了 655,238 股。89.06% 的股票目前由對沖基金和其他機構投資者持有。</p>
<h2>關於 Recursion Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Recursion Pharmaceuticals, Inc.是一家臨牀階段的生物技術公司，致力於通過整合生物學、化學、自動化、數據科學和工程等技術創新來解碼生物學，以工業化藥物發現。該公司開發的 REC-994 正在進行治療腦血管畸形的二期臨牀試驗；REC-2282 正在進行治療神經纖維瘤病 2 型的二期/三期臨牀試驗；REC-4881 正在進行治療家族性腺瘤性息肉病的一期 b/二期臨牀試驗；REC-3964 正在進行治療艱難梭狀芽胞桿菌感染的一期臨牀試驗；REC-4881 正在進行治療 AXIN1 或 APC 突變癌症的二期臨牀試驗。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Recursion Pharmaceuticals 更好</li>
<li>5.00 美元以下的最佳股票</li>
<li>第一季度內部人士購買的三隻大型股：買入、賣出或持有</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>三隻在 2025 年市場低迷中逆勢而上的新股</li>
<li>如何逐步購買便宜股票</li>
<li>三隻以折扣價交易的高收益分紅股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Recursion Pharmaceuticals 嗎？</h2>
<p>在考慮 Recursion Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Recursion Pharmaceuticals 並不在名單上。</p>
<p>雖然 Recursion Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RXRX

<p>Recursion Pharmaceuticals（納斯達克代碼：RXRX）經歷了強勁的交易量，共交易了 990 萬股，較前一交易日下降了 16%。該股票收盤價為 5.68 美元，略低於前一交易日的收盤價 5.76 美元。分析師的評級不一，目標價範圍從 6.00 美元到 11.00 美元不等。公司報告的季度每股收益為（0.53 美元），未達到預期，收入為 460 萬美元，遠低於預期。機構投資者持有該股票的 89.06%，顯示出對這家專注於創新藥物發現公司的強烈興趣</p>

<p>Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares saw strong trading volume on Monday . 9,916,028 shares changed hands during trading, a decline of 16% from the previous session's volume of 11,771,491 shares.The stock last traded at $5.68 and had previously closed at $5.76.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.（納斯達克代碼：RXRX - 獲取免費報告）週一的交易量強勁。交易中共成交 9,916,028 股，較前一交易日的 11,771,491 股下降了 16%。該股最後交易價格為 5.68 美元，前一交易日收盤價為 5.76 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?</li>
</ul>
<div class="lb-trans"><ul>
<li>突然崛起：Recursion Pharmaceuticals 是 NVIDIA 的 AI 寵兒嗎？</li>
</ul>
</div><p>RXRX has been the topic of a number of analyst reports. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a &#34;market perform&#34; rating on the stock in a research note on Friday, February 28th. Morgan Stanley lowered their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Thursday. Cowen restated a &#34;hold&#34; rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. KeyCorp lowered their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, January 8th. Finally, Needham &amp; Company LLC restated a &#34;buy&#34; rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average price target of $8.20.</p>
<div class="lb-trans"><p>RXRX 一直是多份分析師報告的主題。Leerink Partners 在 2 月 28 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 7.00 美元下調至 6.00 美元，並對該股給予 “市場表現” 評級。摩根士丹利在週四的研究報告中將 Recursion Pharmaceuticals 的目標價從 10.00 美元下調至 8.00 美元，並給予 “等權重” 評級。Cowen 在 2 月 28 日的研究報告中重申了對 Recursion Pharmaceuticals 的 “持有” 評級。KeyCorp 在 1 月 8 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 12.00 美元下調至 10.00 美元，並給予 “超配” 評級。最後，Needham &amp; Company LLC 在 4 月 8 日的研究報告中重申了 “買入” 評級，並對 Recursion Pharmaceuticals 的目標價設定為 11.00 美元。四位分析師對該股給予 “持有” 評級，兩位分析師給予 “買入” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “持有”，平均目標價為 8.20 美元。</p>
</div><p><strong>View Our Latest Analysis on RXRX</strong></p>
<div class="lb-trans"><p><strong>查看我們對 RXRX 的最新分析</strong></p>
</div><h2>Recursion Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 價格表現</h2>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技處於邊緣：兩隻潛力巨大的股票</li>
</ul>
</div><p>The stock's fifty day moving average price is $6.83 and its 200-day moving average price is $6.83. The firm has a market cap of $2.19 billion, a PE ratio of -3.56 and a beta of 1.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.</p>
<div class="lb-trans"><p>該股的 50 日移動平均價格為 6.83 美元，200 日移動平均價格也為 6.83 美元。該公司的市值為 21.9 億美元，市盈率為-3.56，貝塔值為 1.00。公司的債務與股本比率為 0.04，流動比率為 4.35，速動比率為 4.35。</p>
</div><p>Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's revenue was down 57.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.42) EPS. As a group, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals（納斯達克代碼：RXRX - 獲取免費報告）最近在 2 月 28 日發佈了季度財報。公司報告季度每股收益（EPS）為-0.53 美元，低於分析師共識預期的-0.36 美元，差距為-0.17 美元。該季度的營業收入為 460 萬美元，而分析師預期為 1904 萬美元。Recursion Pharmaceuticals 的淨利潤率為-579.52%，股本回報率為-76.56%。該公司的收入同比下降了 57.8%。在去年同期，該公司每股收益為-0.42 美元。整體來看，股票分析師預計 Recursion Pharmaceuticals, Inc.在當前財年將發佈-1.57 美元的每股收益。</p>
</div><h2>Institutional Trading of Recursion Pharmaceuticals</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 的機構交易</h2>
</div><ul>
<li>AI Pharma: 2 Paths to AI-Powered Drug Investment</li>
</ul>
<div class="lb-trans"><ul>
<li>AI 製藥：通往 AI 驅動藥物投資的兩條路徑</li>
</ul>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after acquiring an additional 9,737,196 shares during the last quarter. Softbank Group CORP. purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $99,152,000. State Street Corp increased its holdings in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. Novo Holdings A S purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $68,375,000. Finally, Geode Capital Management LLC lifted its holdings in Recursion Pharmaceuticals by 12.1% in the fourth quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock valued at $41,160,000 after acquiring an additional 655,238 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了對該股的持倉。Vanguard Group Inc.在第四季度將其在 Recursion Pharmaceuticals 的持倉增加了 40.1%。Vanguard Group Inc.目前擁有 34,009,994 股該公司的股票，價值 229,908,000 美元，此前在上個季度增持了 9,737,196 股。軟銀集團在第四季度購買了 Recursion Pharmaceuticals 的新股份，價值約為 99,152,000 美元。State Street Corp 在第三季度將其在 Recursion Pharmaceuticals 的持倉增加了 47.1%。State Street Corp 目前擁有 12,870,272 股該公司的股票，價值 84,815,000 美元，此前在上個季度增持了 4,120,685 股。Novo Holdings A S 在第四季度購買了 Recursion Pharmaceuticals 的新股份，價值約為 68,375,000 美元。最後，Geode Capital Management LLC 在第四季度將其在 Recursion Pharmaceuticals 的持倉增加了 12.1%。Geode Capital Management LLC 目前擁有 6,087,149 股該公司的股票，價值 41,160,000 美元，此前在上個季度增持了 655,238 股。89.06% 的股票目前由對沖基金和其他機構投資者持有。</p>
</div><h2>About Recursion Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Recursion Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.是一家臨牀階段的生物技術公司，致力於通過整合生物學、化學、自動化、數據科學和工程等技術創新來解碼生物學，以工業化藥物發現。該公司開發的 REC-994 正在進行治療腦血管畸形的二期臨牀試驗；REC-2282 正在進行治療神經纖維瘤病 2 型的二期/三期臨牀試驗；REC-4881 正在進行治療家族性腺瘤性息肉病的一期 b/二期臨牀試驗；REC-3964 正在進行治療艱難梭狀芽胞桿菌感染的一期臨牀試驗；REC-4881 正在進行治療 AXIN1 或 APC 突變癌症的二期臨牀試驗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Recursion Pharmaceuticals</li>
<li>Best Stocks Under $5.00</li>
<li>Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>3 Hot New IPOs Defying the 2025 Market Slump</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>3 High-Yield Dividend Stocks Trading at a Discount</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Recursion Pharmaceuticals 更好</li>
<li>5.00 美元以下的最佳股票</li>
<li>第一季度內部人士購買的三隻大型股：買入、賣出或持有</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>三隻在 2025 年市場低迷中逆勢而上的新股</li>
<li>如何逐步購買便宜股票</li>
<li>三隻以折扣價交易的高收益分紅股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Recursion Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Recursion Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Recursion Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Recursion Pharmaceuticals 並不在名單上。</p>
</div><p>While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Recursion Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Recursion Pharmaceuticals（納斯達克股票代碼：RXRX）出現異常高的交易量 - 現在是買入的時機嗎？